Gossamer Bio, Inc. (GOSS) Income Statement
GOSS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsGOSS revenue and net income
Where GOSS's revenue goes
2025Each bar shows an amount and its share of revenue. GOSS kept −351.5% of revenue as net income.
GOSS profit margins
GOSS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −57.7% | — | — | — |
| Gross profit | −58.6% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GOSS quarterly EPS vs estimates
Gossamer Bio beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 4, 2026 (estimate $-5.55).
GOSS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.5M | $114.7M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.0M | $4.2M | $4.4M | $4.4M | $5.2M | $4.3M | $3.1M | $297,000 | $0 | $0 |
| Gross profit | $47.5M | $114.7M | −$4.4M | −$4.4M | −$5.2M | −$4.3M | −$3.1M | −$297,000 | $0 | $0 |
| Research & development | $174.1M | $138.5M | $135.3M | $170.9M | $170.3M | $158.0M | $143.4M | $55.3M | $891,000 | $0 |
| Sales, general & admin | $37.6M | $36.1M | $41.2M | $47.6M | $45.8M | $49.7M | $39.1M | $44.1M | $262,000 | $83,000 |
| Total operating expenses | $210.7M | $174.6M | $183.8M | $218.6M | $216.1M | $206.3M | $182.5M | $99.3M | $1.2M | $83,000 |
| Operating income | −$163.3M | −$59.9M | −$183.8M | −$218.6M | −$216.1M | −$210.6M | −$186.1M | −$149.0M | −$6.7M | −$83,000 |
| Interest income | $2.0M | $1.8M | $2.3M | $1.6M | $761,000 | $3.4M | — | $1.7M | $0 | $0 |
| Interest expense | $11.0M | $11.5M | $13.5M | $13.9M | $19.4M | $12.7M | $0 | $12,000 | $118,000 | $0 |
| Income before taxes | −$170.5M | −$55.6M | −$179.8M | −$229.4M | −$234.0M | −$243.4M | −$180.3M | −$147.0M | −$6.8M | −$83,000 |
| Income taxes | −$88,000 | $893,000 | $10.0M | $10.8M | $15.1M | $8.2M | $511,000 | $2.0M | −$5.4M | −$83,000 |
| Net income | −$170.4M | −$56.5M | −$179.8M | −$229.4M | −$234.0M | −$243.4M | −$180.8M | −$147.0M | −$6.8M | −$83,000 |
| EBITDA | −$158.5M | −$40.0M | −$161.9M | −$211.1M | −$209.4M | −$226.4M | −$179.4M | −$149.0M | −$5.5M | −$83,000 |
| EPS (diluted) | −$0.75 | −$0.26 | −$1.39 | −$2.74 | −$3.12 | −$3.55 | −$3.33 | −$19.16 | −$59.14 | — |
| Gross margin | 97.9% | 100.0% | — | — | — | — | — | — | — | — |
| Operating margin | −336.8% | −52.2% | — | — | — | — | — | — | — | — |
| Net margin | −351.5% | −49.3% | — | — | — | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.2M | $17.0M | $13.8M | $13.3M | $11.5M | $9.9M | $9.4M | $9.5M | $95.8M | $0 | $6.8M | $0 |
| Cost of revenue | $0 | $232,000 | $227,000 | $0 | $0 | $0 | $1.1M | $0 | $992,000 | $986,000 | $1.0M | $1.1M |
| Gross profit | $9.2M | $16.7M | $13.8M | $13.3M | $11.5M | $9.9M | $9.4M | $9.5M | $95.8M | −$986,000 | $5.8M | −$1.1M |
| Research & development | $26.4M | $43.1M | $48.9M | $53.0M | $41.6M | $38.0M | $36.1M | $34.9M | $35.1M | $32.4M | $30.0M | $31.2M |
| Sales, general & admin | $8.9M | $18.7M | $10.9M | $9.4M | $8.7M | $8.7M | $9.4M | $8.5M | $9.4M | $9.6M | $9.8M | $9.3M |
| Total operating expenses | $35.3M | $61.6M | $59.8M | $62.4M | $50.3M | $46.7M | $45.5M | $43.4M | $43.8M | $42.0M | $49.0M | $40.5M |
| Operating income | −$26.1M | −$44.9M | −$46.0M | −$49.1M | −$38.8M | −$36.8M | −$36.1M | −$33.9M | $52.1M | −$42.0M | −$49.0M | −$40.5M |
| Interest income | $268,000 | $354,000 | $447,000 | $687,000 | $542,000 | $294,000 | $744,000 | $430,000 | $1.7M | $344,000 | $310,000 | $405,000 |
| Interest expense | $2.7M | $2.8M | $2.8M | $2.7M | $2.7M | $2.7M | $2.7M | $2.7M | $2.9M | $3.1M | $3.2M | $3.3M |
| Income before taxes | $16.9M | −$46.7M | −$47.3M | −$48.2M | −$38.3M | −$36.6M | −$35.4M | −$31.9M | $53.7M | −$41.9M | −$48.1M | −$40.0M |
| Income taxes | — | — | −$88,000 | — | — | — | −$2.4M | −$1.1M | $4.4M | −$986,000 | −$21.5M | $6.8M |
| Net income | $16.9M | −$46.7M | −$47.2M | −$48.2M | −$38.3M | −$36.6M | −$33.0M | −$30.8M | $49.2M | −$41.9M | −$48.1M | −$40.0M |
| EBITDA | −$71.2M | −$43.7M | −$44.3M | −$45.3M | −$35.3M | −$33.5M | −$31.6M | −$28.1M | $57.6M | −$37.8M | −$43.9M | −$35.6M |
| EPS (diluted) | −$0.20 | −$0.20 | −$0.21 | −$0.21 | −$0.17 | −$0.16 | −$0.15 | −$0.14 | $0.22 | −$0.19 | −$0.21 | −$0.21 |
| Gross margin | 100.0% | 98.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 85.2% | — |
| Operating margin | −282.2% | −264.6% | −333.6% | −369.4% | −337.4% | −372.2% | −385.2% | −357.8% | 54.3% | — | −722.7% | — |
| Net margin | 182.9% | −275.2% | −342.3% | −362.7% | −333.1% | −370.5% | −352.2% | −324.9% | 51.4% | — | −709.7% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GOSS's financial statements (latest annual report filed March 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GOSS financial results
In fiscal year 2025 (ended December 31, 2025), Gossamer Bio reported revenue of $48.5 million, down 57.7% from the year before. It had a net loss of $170.4 million, a net profit margin of −351.5%. Diluted earnings per share came to −$0.75.
See the GOSS stock overview for the latest quote and news, or the GOSS chart for price history and technical indicators.
GOSS income statement FAQ
What is Gossamer Bio's annual revenue?
Gossamer Bio reported total revenue of $48.5 million for fiscal year 2025, which ended on December 31, 2025. That was down 57.7% from $114.7 million the previous year.
Is Gossamer Bio profitable?
No. Gossamer Bio reported a net loss of $170.4 million in fiscal 2025, a net profit margin of −351.5%; its operating margin was −336.8%.
What is Gossamer Bio's gross margin?
Gossamer Bio's gross margin was 97.9% in fiscal 2025: for every $100 of revenue, Gossamer Bio kept $98 after the direct cost of its products and services.
How much does Gossamer Bio spend on research and development?
Gossamer Bio spent $174.1 million on research and development in fiscal 2025, 359.2% of revenue.
What are Gossamer Bio's earnings per share?
Gossamer Bio earned $-0.75 per diluted share in fiscal 2025, compared with $-0.26 a year earlier.
When will Gossamer Bio report its next earnings?
Gossamer Bio is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Gossamer Bio's fiscal year end?
Gossamer Bio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 17, 2026.